INTAJAC 5MG

About

INTAJAC 5MG is a Janus Kinase (JAK) inhibitor, such as Tofacitinib, used in the treatment of various autoimmune and inflammatory conditions. It works by selectively inhibiting the activity of specific JAK enzymes (JAK1 and JAK3), which are crucial components of signaling pathways involved in immune and inflammatory responses. By blocking these pathways, INTAJAC modulates the production of cytokines and growth factors, thereby reducing inflammation and immune system overactivity.

This targeted action helps to alleviate symptoms and slow disease progression in conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is administered orally, typically once or twice daily, offering a convenient and effective treatment option for patients who may not have responded adequately to conventional therapies.

Uses

• Treatment of moderate to severe rheumatoid arthritis.
• Management of psoriatic arthritis.
• Therapy for ulcerative colitis.
• Treatment of ankylosing spondylitis (some JAK inhibitors).

Directions For Use

Take one tablet orally, once or twice daily, with or without food, as prescribed by your doctor.

Benefits

• Reduces inflammation and immune overactivity.
• Alleviates joint pain and swelling.
• Improves physical function and quality of life.
• Slows disease progression in chronic conditions.
• Effective in patients who failed other therapies.
• Offers a targeted oral treatment option.

Side Effects

• Upper respiratory tract infections.
• Headache.
• Diarrhea.
• Nausea.
• Nasopharyngitis.
• Increased risk of serious infections (e.g., herpes zoster).
• Elevated cholesterol levels.
• Elevated liver enzymes.
• Anemia.
• Lymphopenia (low lymphocyte count).
• Thrombosis (DVT, PE, arterial thrombosis) (rare but serious).
• Malignancies (e.g., lymphoma, lung cancer) (rare).

Safety Measures

• Alcohol - Limit alcohol intake, especially if there is a risk of liver enzyme elevation or gastrointestinal upset.
• Pregnancy - INTAJAC is not recommended during pregnancy due to potential fetal harm. Women of childbearing potential should use effective contraception.
• Breastfeeding - It is unknown if INTAJAC is excreted in human milk. Breastfeeding is not recommended during treatment.
• Liver - Use with caution in patients with moderate hepatic impairment; dose adjustments may be necessary. Not recommended in severe hepatic impairment.
• Kidney - Dose adjustments are necessary for patients with moderate to severe renal impairment.
• Lung - Increased risk of serious infections, including opportunistic infections, which can affect the lungs. Monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.